| Not Yet Recruiting | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Tr Breast Cancer | Phase 2 | 2026-11-04 |
| Not Yet Recruiting | Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial Head and Neck Squamous Cell Carcinoma HNSCC | Phase 3 | 2026-06-30 |
| Not Yet Recruiting | SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC Non-Small Cell Lung Cancer | Phase 2 | 2026-04-30 |
| Recruiting | Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | 2026-04-20 |
| Not Yet Recruiting | Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles Embryo Culture, Embryo Culture Media, Embryo Quality | N/A | 2026-04-15 |
| Not Yet Recruiting | Effects and Mechanisms of Dietary Carbohydrate Intake and Quality on Glucose and Lipid Metabolism Metabolic Syndrome (MetS), Metabolic Syndrome Risk Factors | N/A | 2026-04-13 |
| Not Yet Recruiting | PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unrese Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2026-04-10 |
| Not Yet Recruiting | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer Gastric Adenocarcinoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy Renal Cell Carcinoma (RCC), Renal Function Abnormal | N/A | 2026-04-01 |
| Recruiting | A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negat HER 2 Negative Breast Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | A Short-Bout Combined Aerobic and Resistance Exercise Program in Older Adults With Diabetes and Probable Sarco Sarcopenia, Diabetes | N/A | 2026-04-01 |
| Not Yet Recruiting | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderl Double Expressor DLBCL | Phase 1 / Phase 2 | 2026-04-01 |
| Recruiting | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasop Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resecta Pancreatic Cancer Resectable | Phase 2 | 2026-03-31 |
| Not Yet Recruiting | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | 2026-03-31 |
| Recruiting | Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocri Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Phase 2 | 2026-03-27 |
| Recruiting | Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenva Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer | Phase 2 | 2026-03-23 |
| Recruiting | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated | Phase 3 | 2026-03-20 |
| Not Yet Recruiting | TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellu Hepato Cellular Carcinoma (HCC) | Phase 2 | 2026-03-18 |
| Recruiting | Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer Colorectal Cancer (CRC) | Phase 2 | 2026-03-15 |
| Not Yet Recruiting | Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lu Lung Cancer (NSCLC) | Phase 2 | 2026-03-15 |
| Recruiting | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasoph Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2026-03-12 |
| Not Yet Recruiting | Construction and Evaluation of a Flipped Discharge Model for Stomates With Colorectal Cancer Colorectal Cancer, Stoma | N/A | 2026-03-10 |
| Not Yet Recruiting | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | Phase 2 | 2026-03-05 |
| Not Yet Recruiting | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | 2026-03-01 |
| Not Yet Recruiting | ArcFlex Sheath in TAVR Trial Valve Disease, Aortic | N/A | 2026-03-01 |
| Not Yet Recruiting | Theory-Based Parenting Intervention for Preschool Children's Health Behaviors Preschool Children's Health Behaviors, Parental Support | N/A | 2026-02-28 |
| Not Yet Recruiting | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | 2026-02-28 |
| Not Yet Recruiting | Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metast Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis | Phase 2 | 2026-02-24 |
| Not Yet Recruiting | Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy | N/A | 2026-02-24 |
| Not Yet Recruiting | Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced O Oral Cancer, Oropharyngeal Cancer | Phase 3 | 2026-02-24 |
| Not Yet Recruiting | Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL Natural Killer/T-cell Lymphoma | — | 2026-02-15 |
| Not Yet Recruiting | Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer Penile Cancer | Phase 2 | 2026-02-10 |
| Recruiting | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2026-02-10 |
| Recruiting | A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for Hig Nasopharangeal Cancer | Phase 2 | 2026-02-04 |
| Recruiting | PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Re Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma | Phase 2 | 2026-02-03 |
| Not Yet Recruiting | FMD and Neoadjuvant Chemo-immunotherapy in TNBC Breast Cancer | Phase 2 | 2026-02-01 |
| Enrolling By Invitation | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acut Acute Lymphoblastic Leukemia | — | 2026-02-01 |
| Not Yet Recruiting | FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cho Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasop Nasopharyngeal Carcinoma (NPC) | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors KRAS G12V, KRAS G12D, Solid Tumor | EARLY_Phase 1 | 2026-02-01 |
| Not Yet Recruiting | SBRT Versus Surgical Resection for Small HCC Hepatocellular Carcinoma (HCC) | Phase 3 | 2026-02-01 |
| Not Yet Recruiting | A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) Cancer Therapy-induced Thrombocytopenia (CTIT) | Phase 2 | 2026-01-31 |
| Not Yet Recruiting | Magnetic Tracking and ECG-Guided Tip Confirmation System for PICCs Peripherally Inserted Central Catheters | — | 2026-01-30 |
| Active Not Recruiting | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectab Hepatocellular Carcinoma (HCC) | Phase 2 | 2026-01-23 |
| Not Yet Recruiting | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | 2026-01-15 |
| Recruiting | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab | Phase 2 | 2026-01-14 |
| Recruiting | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 2 | 2026-01-12 |
| Active Not Recruiting | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic | Phase 3 | 2026-01-06 |
| Recruiting | Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failu Hepatocellulcar Carcinoma | Phase 2 | 2026-01-05 |
| Not Yet Recruiting | A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Brea Locally Advanced or Metastatic Breast Cancer | Phase 2 | 2026-01-05 |
| Not Yet Recruiting | A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line an Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | 2026-01-01 |
| Recruiting | A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Lung Cancer (NSCLC) | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and Mature T-cell and NK-cell Lymphoma | Phase 1 / Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Gynecological Surgery Laparoscopic Gynecological Surgery | N/A | 2026-01-01 |
| Not Yet Recruiting | PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | 2025-12-29 |
| Not Yet Recruiting | Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Local Advanced or Metastatic NSCLC | Phase 2 | 2025-12-23 |
| Not Yet Recruiting | A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Thymic Epithelial Tumors, Advanced Stage, Second-line Therapy | Phase 2 | 2025-12-22 |
| Not Yet Recruiting | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer Rectal Cancer | Phase 2 | 2025-12-20 |
| Not Yet Recruiting | Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Pat Central Serous Chorioretinopathy (CSC) | — | 2025-12-18 |
| Active Not Recruiting | Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for L Locally Advanced, Resectable | Phase 2 | 2025-12-17 |
| Recruiting | Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis | Phase 3 | 2025-12-15 |
| Not Yet Recruiting | A Virtual Peer Agent for Counseling Adolescents With Stressful Life Events Adolescent - Emotional Problem, Agent, Psychological | N/A | 2025-12-05 |
| Not Yet Recruiting | TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Re Hepatitis B, Hepatocellular Carcinoma (HCC) | N/A | 2025-12-01 |
| Not Yet Recruiting | Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Refractory Metastatic Colorectal Cancer | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 3 | 2025-12-01 |
| Recruiting | A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tum Solid Tumor Cancer, Cancer | Phase 1 | 2025-11-25 |
| Not Yet Recruiting | A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer Colorectal Cancer, MRD, ctDNA | — | 2025-11-24 |
| Not Yet Recruiting | Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors Breast Cancer | Phase 2 | 2025-11-21 |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | 2025-11-21 |
| Recruiting | PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Met Nasopharangeal Cancer, Distant Metastasis | Phase 3 | 2025-11-20 |
| Recruiting | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent | Phase 2 | 2025-11-20 |
| Recruiting | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. Nasopharyngeal Cancinoma (NPC) | Phase 3 | 2025-11-17 |
| Recruiting | Adaptive Immunotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) | Phase 3 | 2025-11-13 |
| Not Yet Recruiting | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy | Phase 2 | 2025-11-10 |
| Recruiting | Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment Hepatocellulcar Carcinoma | Phase 2 | 2025-11-05 |
| Enrolling By Invitation | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcino Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | 2025-11-01 |
| Recruiting | Risk Factors Affecting MSC Efficacy in ACLF Patients Acute-On-Chronic Liver Failure | — | 2025-10-20 |
| Recruiting | Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatme Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma | Phase 2 | 2025-10-17 |
| Not Yet Recruiting | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Adva Endometrial Cancer | Phase 2 | 2025-10-15 |
| Not Yet Recruiting | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stag Small-Cell Lung Cancer (SCLC) | Phase 2 | 2025-10-01 |
| Not Yet Recruiting | Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Child Rhabdomyosarcoma Recurrent, Maintenance Treatment | Phase 2 | 2025-10-01 |
| Not Yet Recruiting | Transcatheter Edge-to-Edge Repair In Moderate and Exertional-Induced Severe MR (TIMER) Mitral Regurgitation Functional | EARLY_Phase 1 | 2025-10-01 |
| Not Yet Recruiting | The IVO-LUNG Study Non Small Cell Lung Cancer (Stage III) | Phase 2 | 2025-10-01 |
| Recruiting | QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma Bone and Soft Tissue Tumors | Phase 2 | 2025-09-28 |
| Not Yet Recruiting | IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx Digestive System Neoplasms | Phase 2 | 2025-09-26 |
| Not Yet Recruiting | Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC Esophageal Cancer, Chemoradiotherapy | Phase 3 | 2025-09-20 |
| Not Yet Recruiting | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer | Phase 2 | 2025-09-20 |
| Not Yet Recruiting | Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcin Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | 2025-09-20 |
| Recruiting | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previousl Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-09-17 |
| Not Yet Recruiting | Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | 2025-09-15 |
| Recruiting | Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer Breast Neoplasms | Phase 3 | 2025-09-15 |
| Recruiting | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) | Phase 2 | 2025-09-15 |
| Not Yet Recruiting | A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in Hi Radiotherapy, High-risk Localized Adrenocortical Carcinoma | N/A | 2025-09-15 |
| Recruiting | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | 2025-09-11 |
| Not Yet Recruiting | MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib | — | 2025-09-05 |
| Not Yet Recruiting | Nintedanib for Improving Reproductive Outcomes in Adenomyosis Adenomyosis of Uterus | Phase 3 | 2025-09-01 |
| Recruiting | Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or R Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | 2025-08-27 |
| Not Yet Recruiting | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2025-08-19 |
| Recruiting | Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for I Squamous Cell Cancer of Head and Neck (SCCHN) | Phase 3 | 2025-08-15 |
| Not Yet Recruiting | Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer Gastric (Cardia, Body) Cancer | Phase 2 | 2025-08-15 |
| Not Yet Recruiting | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngea Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2025-08-15 |
| Not Yet Recruiting | AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Colorectal Cancer, Ivonescimab | Phase 2 | 2025-08-10 |
| Not Yet Recruiting | Feasibility Study of Home Cardiac Rehabilitation Program for Postoperative Children With Congenital Heart Dise Congenital Heart Disease (CHD), Preschool Children, Rehabilitation | N/A | 2025-08-01 |
| Not Yet Recruiting | Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component Artificial Intelligence (AI) in Diagnosis | N/A | 2025-08-01 |
| Recruiting | Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Canc Rectal Cancer Patients | N/A | 2025-08-01 |
| Active Not Recruiting | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-L Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC) | Phase 2 | 2025-08-01 |
| Recruiting | Mechanism and Effect of Novel Metabolites on Valvular Heart Disease Valvular Heart Disease | — | 2025-08-01 |
| Active Not Recruiting | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence R Non-Clear Cell Renal Cell Carcinoma | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable Carcinoma, Non-Small-Cell Lung | Phase 2 | 2025-08-01 |
| Recruiting | Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advance Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy | Phase 2 | 2025-07-20 |
| Recruiting | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy | Phase 2 | 2025-07-20 |
| Recruiting | Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm Diabetes Mellitus, Type 2 Diabetes | N/A | 2025-07-15 |
| Not Yet Recruiting | Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Canc HER2 Positive, Colorectal Cancer (CRC) | Phase 2 | 2025-07-11 |
| Recruiting | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy | Phase 2 | 2025-07-10 |
| Not Yet Recruiting | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC Biliary Tract Carcinoma | Phase 2 | 2025-07-10 |
| Active Not Recruiting | Artificial Intelligence Diagnosis of Different Histopathological Growth Patterns of Colorectal Cancer Liver Me Liver Metastases of Colorectal Cancer | — | 2025-07-09 |
| Recruiting | The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) Resectable Hepatocellular Carcinoma With High Risk of Recurrence | — | 2025-07-05 |
| Not Yet Recruiting | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lympho Peripheral T Cell Lymphoma | Phase 2 | 2025-07-01 |
| Recruiting | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Adva Locally Advanced Non-Small Cell Lung Cancer | Phase 3 | 2025-07-01 |
| Not Yet Recruiting | A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer BRAF V600E-mutant Metastatic Colorectal Cancer | — | 2025-07-01 |
| Withdrawn | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer Metastatic Colorectal Cancer, mCRC | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study Pro Colonoscopy, Colorectal Cancer, First-degree Relatives | N/A | 2025-07-01 |
| Not Yet Recruiting | Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study Advanced EBV-positive Malignant Solid Tumors | Phase 1 | 2025-06-23 |
| Withdrawn | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- Rectal Cancer | Phase 2 | 2025-06-20 |
| Not Yet Recruiting | Effectiveness Evaluation of the "Mosquito-Free Campus" Initiative on Dengue Fever Prevention and Control: A Cl Dengue, Infection Prevention | N/A | 2025-06-15 |
| Recruiting | A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutati EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor | Phase 1 / Phase 2 | 2025-06-09 |
| Recruiting | Omitting CTV for Primary Tumor in LS-SCLC SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect | Phase 3 | 2025-06-03 |
| Not Yet Recruiting | New Triple Therapy in Newly Diagnosed Type 2 Diabetes Diabetes Mellitus | Phase 3 | 2025-06-01 |
| Recruiting | Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection Middle and Low Rectal Cancer, Rectal Cancer Surgery | N/A | 2025-06-01 |
| Active Not Recruiting | Pelvic Floor Peritoneal Closure to Prevent Postoperative Ileus in Mid-Low Rectal Cancer Surgery Rectal Cancer Surgery, Middle and Low Rectal Cancer, Intestinal Obstruction | N/A | 2025-06-01 |
| Recruiting | ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC Colorectal Cancer Metastatic | Phase 1 / Phase 2 | 2025-06-01 |
| Recruiting | Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer BRAF V600 Colorectal Cancer | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Pa Metastatic Colorectal Cancer (CRC) | Phase 2 / Phase 3 | 2025-06-01 |
| Not Yet Recruiting | TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm C Nasopharyngeal Carcinoma (NPC) | Phase 2 | 2025-05-18 |
| Recruiting | TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2025-05-16 |
| Recruiting | Safety and Efficacy of Pucotenlimab in pLECC Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma | Phase 2 | 2025-05-15 |
| Withdrawn | The Application of Lidocaine Cream on Oral Secretions of LMA Removal During the Recovery Period in Ophthalmic Airway Complication of Anaesthesia, Laryngeal Mask Airway Removal, Anesthesia Emergence | Phase 4 | 2025-05-15 |
| Recruiting | Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Car Gastrointestinal Cancers | Phase 3 | 2025-05-15 |
| Recruiting | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC Non-small Cell Lung Cancer (NSCLC) | Phase 2 | 2025-05-10 |
| Recruiting | Risk Assessment for HBV-Related Liver Cancer HBV-related Liver Cirrhosis | — | 2025-05-10 |
| Not Yet Recruiting | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT) | Phase 2 | 2025-05-06 |
| Recruiting | An AI Educational Agent for Medical Machine Learning Courses Medical Education, Artificial Intelligence in Medicine | N/A | 2025-05-01 |
| Not Yet Recruiting | Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma Pheochromocytoma | Phase 2 | 2025-05-01 |
| Not Yet Recruiting | Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Ly Follicular Lymphoma Grade 3A | Phase 2 | 2025-05-01 |
| Not Yet Recruiting | PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC) | Phase 3 | 2025-05-01 |
| Not Yet Recruiting | MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer Colon Cancer (stage II & III) | Phase 2 | 2025-05-01 |
| Not Yet Recruiting | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Bladder Cancer, Muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | 2025-04-30 |
| Recruiting | Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMM Rectal Cancer Patients | Phase 2 | 2025-04-30 |
| Not Yet Recruiting | Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer Colon Cancer | Phase 2 | 2025-04-28 |
| Recruiting | Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501 Lung Cancer (NSCLC) | Phase 2 | 2025-04-20 |
| Not Yet Recruiting | GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2025-04-17 |
| Recruiting | Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastati Ewing Sarcoma | Phase 2 | 2025-04-15 |
| Recruiting | Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC | Phase 2 | 2025-04-15 |
| Recruiting | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantl Mantle Cell Lymphoma (MCL) | Phase 2 | 2025-04-14 |
| Recruiting | Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepat Hepatoblastoma, Pediatric Cancer | N/A | 2025-04-10 |
| Recruiting | A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Br Breast Cancer Invasive | N/A | 2025-04-06 |
| Recruiting | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esoph Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | 2025-04-05 |
| Not Yet Recruiting | Liver Cancer Prognosis Investigation Study Liver Neoplasms | — | 2025-04-01 |
| Recruiting | Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer Colorectal Cancer (CRC), PD-1 Inhibitor, Neoadjuvant Immunotherapy | Phase 2 | 2025-04-01 |
| Not Yet Recruiting | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Rectal Adenocarcinoma | Phase 2 | 2025-04-01 |
| Recruiting | A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With Pancreatic Cancer | Phase 1 | 2025-03-27 |
| Recruiting | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosa Resectable Mucosal Melanoma | Phase 2 | 2025-03-20 |
| Recruiting | Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcino Adrenocortical Carcinoma | Phase 2 | 2025-03-14 |
| Recruiting | Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer Metastatic Prostate Cancer | Phase 2 | 2025-03-01 |
| Recruiting | Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Ly Extranodal Natural Killer/T Cell Lymphoma | Phase 1 | 2025-02-21 |
| Recruiting | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Nasopharyngeal Cancinoma (NPC) | Phase 2 / Phase 3 | 2025-02-21 |
| Recruiting | Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC) | Phase 3 | 2025-02-17 |
| Recruiting | Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC), Distant Metastasis | — | 2025-02-15 |
| Not Yet Recruiting | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatme Follicular Lymphoma (FL) | Phase 2 | 2025-02-01 |
| Recruiting | A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Phase 1 / Phase 2 | 2025-01-14 |
| Not Yet Recruiting | Vunakizumab in Adults with Spondyloarthritis Spondyloarthritis (SpA) | Phase 4 | 2025-01-10 |
| Not Yet Recruiting | DYNAMICS-LYNCH：DNA Methylation Analysis in Stool for Screening of Lynch Syndrome-Associated Colorectal Cancer Colorectal Cancer Screening, Lynch Syndrome | — | 2025-01-10 |
| Recruiting | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2025-01-10 |
| Recruiting | GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcino Nasopharyngeal Carcinoma | Phase 2 | 2025-01-03 |
| Recruiting | HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-01-03 |
| Not Yet Recruiting | SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellul Unresectable Hepatocellular Carcinoma (HCC) | Phase 2 / Phase 3 | 2025-01-01 |
| Recruiting | Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | 2025-01-01 |
| Recruiting | TACE Combined Surgery for the Resectable Huge HCC Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer | — | 2025-01-01 |
| Recruiting | Probiotics in Advanced Urothelial Carcinoma Advanced Urothelial Carcinoma, Probiotics, Immunotherapy | Phase 2 | 2025-01-01 |
| Not Yet Recruiting | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL) | Phase 2 | 2025-01-01 |
| Recruiting | Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy | Phase 2 | 2024-12-31 |
| Recruiting | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus Renal Cell Carcinoma Stage I | Phase 2 | 2024-12-30 |
| Recruiting | Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy | Phase 2 | 2024-12-27 |
| Not Yet Recruiting | Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Pros Relapsed or Metastatic Thymic Cancer, First-line Treatment | Phase 2 | 2024-12-20 |
| Recruiting | The Optimal Radioimmunotherapy Combinations for Advanced TNBC Triple-Negative Breast Cancer (TNBC) | Phase 2 | 2024-12-20 |
| Recruiting | TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody | N/A | 2024-12-13 |
| Recruiting | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stag Lung Cancer (NSCLC) | Phase 2 | 2024-12-10 |
| Recruiting | ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC Lung Cancer, Nonsmall Cell | Phase 2 | 2024-12-01 |
| Completed | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant C Rectal Cancer | Phase 2 | 2024-12-01 |
| Recruiting | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients w Chemotherapy-Induced Neutropenia | Phase 2 | 2024-12-01 |
| Completed | Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients Breast Cancer | — | 2024-12-01 |
| Recruiting | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunot Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy | Phase 3 | 2024-11-30 |
| Recruiting | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Toripalimab, Surufatinib, Chemoradiotherapy | Phase 2 | 2024-11-30 |
| Recruiting | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) | Phase 3 | 2024-11-27 |
| Not Yet Recruiting | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatmen Biliary Tract Cancer, Second Line Treatment, Chemotherapy | Phase 2 / Phase 3 | 2024-11-25 |
| Recruiting | WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Qualit Neurodevelopmental Disorders | N/A | 2024-11-20 |
| Recruiting | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Thymoma | Phase 2 | 2024-11-20 |
| Recruiting | A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC) Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis | — | 2024-11-19 |
| Not Yet Recruiting | Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinom Nasopharyngeal Carcinoma (NPC), Cognitive Function | — | 2024-11-15 |
| Recruiting | Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL Primary Mediastinal Diffuse Large B-cell Lymphoma | Phase 2 | 2024-11-12 |
| Recruiting | Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevo Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics | Phase 4 | 2024-11-12 |
| Not Yet Recruiting | A TTM-based Smoking Cessation Intervention in Helping Expectant Fathers to Quit Smoking and Maintain Abstinenc Smoking Cessation, Behavioral Intervention | N/A | 2024-11-04 |
| Recruiting | Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy Esophageal Cancer, Surgery-Complications | — | 2024-11-04 |
| Not Yet Recruiting | A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemothe NSCLC, Brain Metastasases | Phase 2 | 2024-11-02 |
| Active Not Recruiting | Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease Lower Extremity, Photoacoustic | — | 2024-11-01 |
| Recruiting | Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | 2024-11-01 |
| Recruiting | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | Nomogram for Predicting Biliary Complication Liver Transplant Disorder | — | 2024-11-01 |
| Recruiting | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Lung Cancer Stage III, Mutation | Phase 2 | 2024-11-01 |
| Recruiting | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neurob Neuroblastoma | Phase 1 | 2024-11-01 |
| Recruiting | Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer Colorectal Cancer, Microsatellite Instability High | Phase 3 | 2024-11-01 |
| Recruiting | Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study Soft Tissue Sarcoma (STS) | N/A | 2024-11-01 |
| Recruiting | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | Phase 2 | 2024-10-30 |
| Recruiting | Arsenous Acid for Refractory Triple-Negative Breast Cancer Breast Cancer | Phase 2 | 2024-10-23 |
| Recruiting | Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study Classical Hodgkin Lymphoma | Phase 2 | 2024-10-23 |
| Recruiting | Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | 2024-10-22 |
| Active Not Recruiting | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carc Nasopharyngeal Cancinoma (NPC) | Phase 3 | 2024-10-21 |
| Enrolling By Invitation | Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Colorectal Cancer Surgery Laparoscopic Colorectal Cancer Surgery | N/A | 2024-10-15 |
| Recruiting | Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis | — | 2024-10-04 |
| Recruiting | dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab | N/A | 2024-10-01 |
| Recruiting | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma, Variceal Bleeding | N/A | 2024-10-01 |
| Not Yet Recruiting | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line System Hepatocellular Carcinoma, Oligoprogression | Phase 2 | 2024-10-01 |
| Recruiting | Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC Hepatocellular Carcinoma, Microwave Ablation, Donafenib | N/A | 2024-10-01 |
| Recruiting | HAIC Compared With TACE in Huge Hepatocellular Carcinoma Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer | — | 2024-10-01 |
| Recruiting | The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carc Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy | N/A | 2024-10-01 |
| Recruiting | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy | N/A | 2024-10-01 |
| Recruiting | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Ca Squamous Cell Carcinoma of Head and Neck | Phase 3 | 2024-09-20 |
| Not Yet Recruiting | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lun NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer) | Phase 2 | 2024-09-20 |
| Recruiting | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic | Phase 3 | 2024-09-18 |
| Not Yet Recruiting | Hematoporphyrin Photodynamic Therapy for Esophageal Cancer Esophageal Cancer, Photodynamic Therapy | Phase 4 | 2024-09-18 |
| Recruiting | SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Pat Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | 2024-09-11 |
| Recruiting | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC Hepatocellular Carcinoma, Beyond Milan Criteria | Phase 2 | 2024-09-01 |
| Recruiting | Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy Graves Ophthalmopathy, Surgery | N/A | 2024-09-01 |
| Not Yet Recruiting | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer Ovarian Cancer | Phase 2 | 2024-09-01 |
| Recruiting | Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Pa Pancreatic Cancer, Neoadjuvant Chemoradiotherapy, Immunonutrition | N/A | 2024-08-26 |
| Not Yet Recruiting | TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced High Risk Locally Advanced Nasopharyngeal Carcinoma | Phase 3 | 2024-08-20 |
| Recruiting | Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Gre Colon Cancer | N/A | 2024-08-10 |
| Completed | Adaptive Therapy for Post-Second-Line Advanced Breast Cancer HER2-negative Metastatic Breast Cancer | Phase 2 | 2024-08-04 |
| Recruiting | Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyn Nasopharyngeal Carcinoma (NPC) | Phase 1 | 2024-08-02 |
| Recruiting | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation | N/A | 2024-08-01 |
| Recruiting | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI Non-small Cell Lung Cancer | Phase 3 | 2024-08-01 |
| Not Yet Recruiting | The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy Prostate Cancer | Phase 2 | 2024-08-01 |
| Recruiting | Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) Diffuse Large B Cell Lymphoma | Phase 2 | 2024-08-01 |
| Recruiting | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achi Nasopharyngeal Carcinoma, De-escalation Therapy | Phase 3 | 2024-07-30 |
| Recruiting | Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Prog Metastatic Castration-resistant Prostate Cancer | — | 2024-07-24 |
| Active Not Recruiting | Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage | Phase 2 | 2024-07-23 |
| Recruiting | Adebrelimab and Chemoradiotherapy in High-risk LANPC Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | 2024-07-23 |
| Recruiting | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study Colorectal Cancer Metastatic | Phase 2 | 2024-07-18 |
| Recruiting | Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q | Phase 2 | 2024-07-17 |
| Active Not Recruiting | Prognostic Significance of the Uncertain Resection in NSCLC Non Small Cell Lung Cancer, Residual; State | — | 2024-07-16 |
| Recruiting | SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2024-07-15 |
| Recruiting | Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherap Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma | — | 2024-07-15 |
| Recruiting | GOS and the Management of Hyperuricemia Subjects With Hyperuricemia | N/A | 2024-07-15 |
| Not Yet Recruiting | Promoting Atrial Fibrillation Screening in Primary Care Atrial Fibrillation New Onset | N/A | 2024-07-01 |
| Completed | Comparison of General Anesthesia Hemodynamics Between R and P in Patients Undergoing Laparoscopic Hepatectomy Hypotension During Surgery | Phase 3 | 2024-06-20 |
| Not Yet Recruiting | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-labe Hepatocellular Carcinoma | Phase 2 | 2024-06-19 |
| Recruiting | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2024-06-18 |
| Recruiting | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen Rhabdomyosarcoma, Pediatric Cancer | Phase 1 / Phase 2 | 2024-06-06 |
| Not Yet Recruiting | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer Colorectal Cancer | Phase 1 / Phase 2 | 2024-06-05 |
| Completed | The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Ca Prostate Cancer Metastatic Disease, PET / CT | — | 2024-06-02 |
| Withdrawn | Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). Lung Cancer | Phase 2 | 2024-06-01 |
| Not Yet Recruiting | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment Primary Mediastinal Large B Cell Lymphoma | Phase 2 | 2024-06-01 |
| Recruiting | TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer Penile Cancer | Phase 2 | 2024-05-31 |
| Recruiting | Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | — | 2024-05-29 |
| Recruiting | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer Colorectal Cancer | Phase 2 / Phase 3 | 2024-05-24 |
| Recruiting | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients DLBCL | Phase 2 | 2024-05-23 |
| Recruiting | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell L Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer | Phase 2 | 2024-05-22 |
| Recruiting | bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma Liver Diseases, Hepatocellular Carcinoma, Immunotherapy | N/A | 2024-05-20 |
| Recruiting | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC Liver Diseases, Hepatocellular Carcinoma, Immunotherapy | N/A | 2024-05-20 |
| Recruiting | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 3 | 2024-05-17 |
| Recruiting | Prebiotics and the Management of Hyperuricemia Subjects With Hyperuricemia | N/A | 2024-05-15 |
| Enrolling By Invitation | A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectom Sigmoid Cancer | N/A | 2024-05-06 |
| Not Yet Recruiting | Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast Cancer Breast Cancer, Ipsilateral Supraclavicular Lymph Node Metastasis | N/A | 2024-05-01 |
| Not Yet Recruiting | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial Nasopharyngeal Carcinoma | EARLY_Phase 1 | 2024-05-01 |
| Completed | Dyadic Intervention for Psychological Distress of Patients With Colorectal Cancer and Their Spouses Colorectal Cancer | N/A | 2024-05-01 |
| Recruiting | BAI-BACE for Advanced Lung Squamous Cell Carcinoma Squamous Cell Carcinoma | N/A | 2024-05-01 |
| Recruiting | PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC Pancreatic Adenocarcinoma Metastatic | Phase 2 | 2024-04-30 |
| Recruiting | A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent | — | 2024-04-24 |
| Not Yet Recruiting | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cance Pancreatic Cancer | Phase 2 | 2024-04-17 |
| Recruiting | Individualized Elective Neck Irradiation in NPC Patients Nasopharyngeal Carcinoma | Phase 3 | 2024-04-16 |
| Not Yet Recruiting | A Randomized Controlled Trial of the Safety and Efficacy of Robotic Telesurgery Versus Laparoscopic Surgery Liver Cancer, Renal Cancer, Rectal Cancer | N/A | 2024-04-15 |
| Recruiting | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) Hepatocellular Carcinoma | Phase 2 | 2024-04-05 |
| Completed | Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients Smoking Cessation | — | 2024-04-05 |
| Unknown | Adolescents' Non-suicidal Behavior and Perception of Parents' Negative Emotional Expression and Family Communi Adolescents | — | 2024-04-01 |
| Not Yet Recruiting | Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Re Artificial Intelligence Supported Image Reviewing | — | 2024-04-01 |
| Recruiting | Factors Associated With Posttransplant Cardiac Outcomes Cardiovascular Diseases, Liver Transplantation | — | 2024-04-01 |
| Recruiting | Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery | N/A | 2024-03-25 |
| Recruiting | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2024-03-19 |
| Recruiting | De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for N Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY | N/A | 2024-03-04 |
| Active Not Recruiting | Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) Esophagus Cancer | Phase 2 | 2024-03-02 |
| Recruiting | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-03-01 |
| Not Yet Recruiting | Myeloprotection With Trilaciclib in Pan-cancer Population Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer | Phase 2 | 2024-03-01 |
| Recruiting | Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Canc MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis | Phase 2 | 2024-03-01 |
| Not Yet Recruiting | Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER) Mitral Regurgitation | N/A | 2024-03-01 |
| Recruiting | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response Nasopharyngeal Carcinoma | Phase 3 | 2024-03-01 |
| Recruiting | Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastase Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases | N/A | 2024-02-02 |
| Recruiting | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 / Phase 3 | 2024-02-01 |
| Recruiting | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients Colorectal Cancer, Liver Metastases | Phase 2 / Phase 3 | 2024-02-01 |
| Not Yet Recruiting | Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation | Phase 2 | 2024-02-01 |
| Recruiting | Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) Natural Killer T-cell Lymphoma | Phase 2 | 2024-01-27 |
| Recruiting | Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma (HNSCC) | N/A | 2024-01-26 |
| Recruiting | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer Breast Cancer, Refractory Breast Carcinoma | Phase 3 | 2024-01-15 |
| Recruiting | Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM Colorectal Neoplasms Malignant | Phase 3 | 2024-01-15 |
| Recruiting | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy | Phase 3 | 2024-01-10 |
| Completed | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGF Non-small Cell Lung Cancer Metastatic | Phase 2 | 2024-01-01 |
| Recruiting | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy Rectal Cancer | Phase 2 | 2024-01-01 |
| Recruiting | The Cold Ischemia Robot-assisted Partial Nephrectomy Renal Cell Carcinoma, Renal Function Abnormal | N/A | 2024-01-01 |
| Active Not Recruiting | Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Nasopharyngeal Carcinoma | — | 2024-01-01 |
| Recruiting | Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment o Rhabdomyosarcoma, Child | Phase 2 | 2023-12-30 |
| Recruiting | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcin Hepatocellular Carcinoma | Phase 3 | 2023-12-26 |
| Unknown | Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer Colorectal Cancer, Liver Metastases, MSS | Phase 2 | 2023-12-19 |
| Recruiting | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Ra Nasopharyngeal Carcinoma | — | 2023-12-18 |
| Not Yet Recruiting | A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma Potentially Resectable Hepatocellular Carcinoma | Phase 2 | 2023-12-15 |
| Not Yet Recruiting | The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC Patients Sodium Fluoride | Phase 2 | 2023-12-15 |
| Recruiting | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF Malignant Ascites | Phase 2 | 2023-12-14 |
| Recruiting | SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionall SBRT | Phase 2 | 2023-12-07 |
| Active Not Recruiting | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Local Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity | Phase 2 | 2023-12-01 |
| Active Not Recruiting | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemora Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy | Phase 2 | 2023-12-01 |
| Completed | Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC Hepatocellular Carcinoma, Lenvatinib | — | 2023-12-01 |
| Unknown | Health Status and the Need for Social Return of Drug Abusers in Guangdong Province Drug Use | — | 2023-11-15 |
| Completed | The Effects of a Large Language Model on Clinical Questioning Skills Cataract, Glaucoma, Diabetic Retinopathy | N/A | 2023-11-13 |
| Unknown | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma Renal Cell Carcinoma | Phase 2 | 2023-11-11 |
| Recruiting | Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Le Metastatic Colorectal Cancer | Phase 2 | 2023-11-09 |
| Recruiting | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | Phase 2 | 2023-11-01 |
| Recruiting | Liposomal Bupivacaine vs Ropivacaine for TAPBs Abdominal Tumor, Postoperative Analgesia, Liposomal Bupivacaine | Phase 3 | 2023-11-01 |
| Not Yet Recruiting | Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Colorectal Cancer | Phase 2 | 2023-11-01 |
| Recruiting | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity | Phase 3 | 2023-10-31 |
| Unknown | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer Locally Advanced Rectal Cancer | Phase 2 | 2023-10-24 |
| Not Yet Recruiting | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patient Locally Advanced Pancreatic Cancer | Phase 2 | 2023-10-23 |
| Completed | Effect of the PIEB Versus CEI on the Quality of Postoperative Recovery in Patients Undergoing VATS Lobectomy Video-assisted Thoracic Surgery | N/A | 2023-10-20 |
| Not Yet Recruiting | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer | Phase 2 | 2023-10-18 |
| Suspended | Impact of an Educational Video on Satisfaction After Glaucoma Surgery Glaucoma | N/A | 2023-10-10 |
| Recruiting | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemo Nasopharyngeal Carcinoma, De-escalation Therapy | Phase 3 | 2023-10-09 |
| Recruiting | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma Classic Hodgkin Lymphoma | Phase 2 | 2023-10-01 |
| Recruiting | Evaluation of Phacogoniotomy in Medically-controlled POAG Glaucoma, Open-Angle, Cataract Complicated, Goniotomy | N/A | 2023-09-28 |
| Withdrawn | Efficacy and Safety of Tocilizumab for TAO Tocilizumab, Thyroid Associated Ophthalmopathy | Phase 2 | 2023-09-23 |
| Unknown | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery DMMR Colorectal Cancer, Anti PD-1, Immunotherapy | Phase 2 | 2023-09-23 |
| Completed | Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus Primary Malignant Melanoma of the Esophagus | — | 2023-09-22 |
| Recruiting | The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radioth GM-CSF | Phase 2 | 2023-09-15 |
| Unknown | Effect of Health Education on Promoting Influenza Vaccination Health Literacy Vaccination; Infection, Influenza | N/A | 2023-09-11 |
| Recruiting | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 3 | 2023-09-07 |
| Unknown | Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma Chemotherapy-Induced Thrombocytopenia | Phase 2 | 2023-09-04 |
| Recruiting | Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chro Breast Cancer | — | 2023-09-01 |
| Recruiting | Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients Chemotherapy Effect, Rectal Cancer | N/A | 2023-09-01 |
| Completed | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | 2023-09-01 |
| Recruiting | Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clini Hepatocellular Carcinoma | Phase 2 | 2023-09-01 |
| Unknown | Effectiveness of Using Interactive Consulting System to Enhance Informed Choice Age-related Cataract | N/A | 2023-09-01 |
| Active Not Recruiting | Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms | Phase 2 | 2023-09-01 |
| Active Not Recruiting | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Che Esophageal Squamous Cell Carcinoma | Phase 1 | 2023-08-31 |
| Unknown | A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standa Locally Advanced Unresectable Gastric Cancer | Phase 2 | 2023-08-25 |
| Recruiting | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy Metastatic Colorectal Cancer | Phase 2 | 2023-08-24 |
| Recruiting | Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY) Non Small Cell Lung Cancer | N/A | 2023-08-16 |
| Recruiting | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | 2023-08-15 |
| Unknown | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasophar Nasopharyngeal Carcinoma, Oral Mucositis | — | 2023-08-14 |
| Recruiting | Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC Non-small Cell Lung Cancer | — | 2023-08-10 |
| Recruiting | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Radiotherapy; Complications | Phase 3 | 2023-08-08 |
| Active Not Recruiting | Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes Type 2 Diabetes | — | 2023-08-02 |
| Unknown | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity | Phase 2 | 2023-08-01 |
| Active Not Recruiting | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | 2023-08-01 |
| Recruiting | Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis Anastomotic Stenosis | N/A | 2023-08-01 |
| Recruiting | MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer Colorectal Cancer | N/A | 2023-07-26 |
| Active Not Recruiting | The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolida Non-small Cell Lung Cancer | Phase 2 | 2023-07-25 |
| Unknown | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer Colorectal Cancer | Phase 2 | 2023-07-18 |
| Recruiting | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Colorectal Cancer | Phase 2 | 2023-07-10 |
| Recruiting | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Limited Stage Small Cell Lung Cancer | Phase 2 / Phase 3 | 2023-07-01 |
| Recruiting | Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Colon Cancer, Neoadjuvant Therapy, Immunotherapy | Phase 2 | 2023-07-01 |
| Recruiting | PaCIFiC-CUP Classifies Cancer of Unknown Primary Unknown Primary Tumors, DNA Methylation | — | 2023-07-01 |
| Unknown | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell NSCLC, Non-small Cell Lung Cancer | Phase 2 | 2023-07-01 |
| Unknown | Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastati Sarcoma | Phase 2 | 2023-07-01 |
| Recruiting | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma Classical Hodgkin Lymphoma | Phase 2 | 2023-06-14 |
| Recruiting | Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases Colorectal Cancer Liver Metastases, Regorafenib | Phase 3 | 2023-06-10 |
| Active Not Recruiting | Effect of IOP Lowering on Progressive HM High Myopia, Intraocular Pressure | N/A | 2023-06-01 |
| Completed | Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Early Diagnosis of Cancer | — | 2023-06-01 |
| Recruiting | Effects of Supplementation of Compound Nutrients on Plasma Homocysteine in Chinese Adults Homocysteine | N/A | 2023-06-01 |
| Unknown | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria Hepatocellular Carcinoma by BCLC Stage | Phase 2 | 2023-06-01 |
| Recruiting | Effects of Digital Therapeutic in Whole Process Management of Lung Cancer Application of Digital Therapeutic in Lung Cancer Whole Process Management | Phase 3 | 2023-06-01 |
| Unknown | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial Hepatocellular Carcinoma | Phase 2 | 2023-05-24 |
| Recruiting | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, De-escaltion Therapy | Phase 3 | 2023-05-20 |
| Recruiting | Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | Phase 2 | 2023-05-17 |
| Completed | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients W Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy | Phase 2 / Phase 3 | 2023-05-14 |
| Unknown | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC Hepatocellular Carcinoma | Phase 3 | 2023-05-10 |
| Active Not Recruiting | Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Can Cervical Cancer, Cervical Carcinoma | Phase 2 | 2023-05-10 |
| Active Not Recruiting | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | 2023-05-08 |
| Recruiting | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Iron-deficiency, Anemia | Phase 2 | 2023-05-05 |
| Unknown | The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age Menstrual Disorder, Premature Ovarian Failure | — | 2023-05-04 |
| Unknown | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 | Phase 2 | 2023-05-01 |
| Completed | A Conversational AI System to Enhance Knowledge About Vaccines and Promote Vaccination Vaccination Hesitancy | N/A | 2023-05-01 |
| Completed | Efficacy of Using Large Language Model to Assist in Diabetic Retinopathy Detection Diagnosis, Diabetic Retinopathy | N/A | 2023-05-01 |
| Completed | Effectiveness of an Interactive Consulting System to Enhance Patients' Decision-making: A Randomized Controlle Age-related Cataract | N/A | 2023-05-01 |
| Unknown | Construction and Validation of Risk Prediction Model for Gastrointestinal Dysfunction of Patient With Colorect Patient With Colorectal Cancer, Surgery | — | 2023-05-01 |
| Recruiting | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC Nasopharyngeal Carcinoma | Phase 3 | 2023-05-01 |
| Recruiting | Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study Colorectal Cancer Metastatic | Phase 2 | 2023-05-01 |
| Unknown | The Investigation of Knowledge and Educational Demand of Sexual and Reproductive Health Among Cancer Survivors Sexual and Reproductive Health | — | 2023-05-01 |
| Recruiting | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2- Gastric Cancer | Phase 3 | 2023-04-30 |
| Unknown | Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishmen Breast Cancer | N/A | 2023-04-12 |
| Completed | The Risk Assessment Scale for Peripherally Inserted Central Venous Catheter (PICC) Related Thrombosis in Cance Thrombosis, Catheter | — | 2023-04-01 |
| Not Yet Recruiting | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Nasopharyngeal Carcinoma, Leucogen, Chemotherapy | Phase 3 | 2023-04-01 |
| Unknown | Influence and Mechanism of Dyadic Coping on Parenting Stress and Parenting Self-Efficacy in Parents of Preterm Premature Infant Disease | — | 2023-03-16 |
| Recruiting | Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brai Brain Metastases, Radiotherapy, EGFR Activating Mutation | Phase 3 | 2023-03-15 |
| Unknown | The Efficacy and Safety of Rifaximin Treatment Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV | EARLY_Phase 1 | 2023-03-09 |
| Unknown | Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2023-03-09 |
| Recruiting | Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial Hepatocellular Carcinoma | Phase 2 | 2023-03-09 |
| Unknown | The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dyna Insulin Pump，Continuous Glucose Monitoring Technology | Phase 4 | 2023-03-07 |
| Recruiting | Evaluation of COVID-19 Immune Barrier and Reinfection Risk COVID-19 Infection, Immunization; Infection | — | 2023-03-06 |
| Recruiting | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment o Hepatocellular Carcinoma | Phase 2 | 2023-03-02 |
| Recruiting | Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC Metastatic Microsatellite-stable Colorectal Cancer | Phase 3 | 2023-03-01 |
| Recruiting | Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | 2023-03-01 |
| Unknown | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in th Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma | — | 2023-03-01 |
| Recruiting | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Ca Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma | — | 2023-03-01 |
| Not Yet Recruiting | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) Advanced Hepatocellular Carcinoma | Phase 3 | 2023-03-01 |
| Unknown | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract C Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer | Phase 1 / Phase 2 | 2023-03-01 |
| Unknown | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2023-02-28 |
| Unknown | A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy Double Express Diffuse Large B-cell Lymphoma | Phase 2 | 2023-02-24 |
| Unknown | Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma Toripalimab, First-line Treatment | Phase 2 | 2023-02-18 |
| Unknown | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | Phase 3 | 2023-02-17 |
| Recruiting | Safety and Efficacy of Two-step Radical Prostatectomy Prostate Cancer | — | 2023-02-15 |
| Unknown | Steroid-Eluting Stent Implant for the Treatment of Radiation-Related Sinusitis Radiation-Induced Mucositis | Phase 3 | 2023-02-11 |
| Completed | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | 2023-02-10 |
| Recruiting | Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) | Phase 1 / Phase 2 | 2023-02-07 |
| Unknown | Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast C Breast Cancer | Phase 2 | 2023-02-01 |
| Completed | Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatmen Metastatic Colorectal Cancer | Phase 1 / Phase 2 | 2023-02-01 |
| Recruiting | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine o Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic | Phase 2 | 2023-02-01 |
| Completed | Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Ca Pancreatic Neoplasms | Phase 2 | 2023-01-30 |
| Unknown | Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Ovarian Cancer | Phase 2 | 2023-01-01 |
| Completed | Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients Breast Cancer | — | 2023-01-01 |
| Unknown | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) Resectable Hepatocellular Carcinoma | Phase 2 | 2023-01-01 |
| Unknown | Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM) Functional Mitral Regurgitation | Phase 4 | 2022-12-23 |
| Unknown | Treatments for Brain Metastases With Poor Prognostic Factors Brain Metastases | — | 2022-12-15 |
| Active Not Recruiting | Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metasta Pancreatic Neoplasms | Phase 2 | 2022-12-12 |
| Unknown | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC Esophageal Squamous Cell Carcinoma, Oligometastatic Disease | Phase 2 | 2022-12-10 |
| Unknown | Artificial Intelligent System for Eye Emergency Triage and Primary Diagnosis Emergencies, Eye Diseases | — | 2022-12-10 |
| Completed | Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface Orbital Neoplasms, Conjunctival Neoplasms, Eye Neoplasms | — | 2022-12-05 |
| Unknown | Validation of a Smartphone-based Intelligent Diagnosis and Measurement for Strabismus Strabismus, Exotropia, Esotropia | — | 2022-12-02 |
| Completed | A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials Malignant Lymphoma, Clinical Trial, COVID-19 | — | 2022-12-01 |
| Unknown | Early Detection of noctUrnal hypoglyCemiA in TypE 2 Diabetes Using Pulse Rate Variability Measured by a Smartw Hypodlycemia | — | 2022-12-01 |
| Not Yet Recruiting | A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcino Nasopharyngeal Carcinoma | N/A | 2022-11-30 |
| Active Not Recruiting | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2022-11-25 |
| Completed | The Association Between Watching Mukbang Videos and the Appetite of Children With Cancer Mukbang | — | 2022-11-24 |
| Active Not Recruiting | Influencing Factors and Trigger Mechanism of Relapse in Expectant Fathers Who Quit Smoking Smoking Cessation | — | 2022-11-23 |
| Unknown | Psychometric Properties of the Chinese Version of the Five-item Relationship Satisfaction Scale Relationship, Family | — | 2022-11-23 |
| Unknown | Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy | N/A | 2022-11-21 |
| Unknown | Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation Brain Metastases | — | 2022-11-20 |
| Recruiting | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC210 Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer | Phase 3 | 2022-11-01 |
| Unknown | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patien EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | 2022-11-01 |
| Unknown | Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors Eyelid Tumor, Xanthelasma Palpebrarum, Pigmented Nevi | — | 2022-11-01 |
| Active Not Recruiting | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children Pediatric Solid Tumor | Phase 1 | 2022-10-25 |
| Recruiting | A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents Hepatocellular Carcinoma | N/A | 2022-10-18 |
| Not Yet Recruiting | Effect of Prebiotics on Blood Pressure Management Hypertension, Gastrointestinal Microbiome | N/A | 2022-10-17 |
| Unknown | Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | — | 2022-10-16 |
| Completed | Comparison of Volume-controlled and Pressure-controlled Ventilation in Clasp-knife Position Mechanical Ventilation, General Anesthesia, Urological Surgery | N/A | 2022-10-15 |
| Unknown | Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(E Advanced Biliary Tract Cancer | Phase 2 | 2022-10-10 |
| Recruiting | Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns Metastatic Breast Cancer | — | 2022-10-10 |
| Unknown | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC Nasopharyngeal Carcinoma | Phase 2 | 2022-10-08 |
| Unknown | A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell L Relapsed and Refractory Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | 2022-10-01 |
| Unknown | Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma Pediatric Soft Tissue Sarcoma | — | 2022-10-01 |
| Completed | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | 2022-09-22 |
| Unknown | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003） Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | 2022-09-20 |
| Active Not Recruiting | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | 2022-09-15 |
| Unknown | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora | Phase 1 / Phase 2 | 2022-09-15 |
| Recruiting | Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Fo Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | Phase 2 | 2022-09-01 |
| Unknown | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC Nasopharyngeal Carcinoma | Phase 2 | 2022-09-01 |
| Recruiting | Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME) Rectal Cancer | — | 2022-08-24 |
| Unknown | Follow-up Strategy for Esophageal Cancer Patients Esophagus Cancer | — | 2022-08-20 |
| Unknown | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer Gastric Adenocarcinoma | Phase 2 | 2022-08-16 |
| Unknown | Correlation of Mukbang Video Watching Behavior,Internet Addition and Mental Health Among General Population Mukbang | — | 2022-08-15 |
| Active Not Recruiting | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation Non-Small Cell Lung Cancer | Phase 2 | 2022-08-01 |
| Completed | Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients Pediatric Cancer | Phase 2 | 2022-08-01 |
| Recruiting | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Witho Colorectal Cancer Metastatic | Phase 2 | 2022-07-29 |
| Unknown | Correlation of Mukbang Video Watching Behavior,Internet Addition and Mental Health Among Adolescent and Youth Mukbang | — | 2022-07-27 |
| Recruiting | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study Hepatocellular Carcinoma | Phase 3 | 2022-07-26 |
| Unknown | Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM Colorectal Cancer Liver Metastases | Phase 2 | 2022-07-25 |
| Recruiting | Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved He Resolved Hepatitis B, CD20 Positive B-cell Lymphoma | Phase 2 | 2022-07-15 |
| Recruiting | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening Nasopharyngeal Carcinoma | — | 2022-07-10 |
| Unknown | Phase II Study of TAEST16001 in Soft Tissue Sarcoma Soft Tissue Sarcoma | Phase 2 | 2022-07-08 |
| Completed | Comparison of Nutrient Content Between Preterm and Term Human Milk: a Systematic Review and Meta-analysis Comparative Nutrient Composition of Preterm and Term Human Milk | — | 2022-07-06 |
| Recruiting | The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With Rectal Cancer | Phase 3 | 2022-07-05 |
| Unknown | The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-w Thalassemia Major, Transfusion-dependent Anemia | Phase 4 | 2022-07-01 |
| Unknown | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma DLBCL | Phase 2 | 2022-07-01 |
| Unknown | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: Nasopharyngeal Carcinoma | Phase 2 | 2022-07-01 |
| Not Yet Recruiting | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TN Nasopharyngeal Carcinoma, TNF, Chemo-radiotherapy | Phase 2 / Phase 3 | 2022-07-01 |
| Recruiting | Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer | N/A | 2022-07-01 |
| Active Not Recruiting | Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma Extranodal Natural Killer T Cell Lymphoma | Phase 1 / Phase 2 | 2022-06-23 |
| Recruiting | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2022-06-21 |
| Recruiting | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 2 | 2022-06-20 |
| Completed | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients Triple Negative Breast Cancer | Phase 2 | 2022-06-15 |
| Unknown | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab C-staged Hepatocellular Carcinoma in BCLC Classification | Phase 3 | 2022-06-15 |
| Active Not Recruiting | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | Phase 3 | 2022-06-10 |
| Recruiting | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy | Phase 2 | 2022-06-08 |
| Suspended | Effect of Probiotics on Blood Pressure Management Hypertension | N/A | 2022-06-03 |
| Unknown | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic | Phase 2 | 2022-06-01 |
| Recruiting | The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemoth Lung Cancer, Esophageal Cancer | — | 2022-06-01 |
| Unknown | Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) Relapsed or Refractory DLBCL | Phase 2 | 2022-06-01 |
| Recruiting | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Na Nasopharyngeal Carcinoma | N/A | 2022-06-01 |
| Unknown | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL Primary Extranodal Lymphoma, DLBCL | Phase 2 | 2022-06-01 |
| Not Yet Recruiting | Umbrella Biomarker-Guided Therapy in NPC Nasopharyngeal Carcinoma | Phase 2 | 2022-06-01 |
| Unknown | Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies Lymphoma | — | 2022-05-31 |
| Completed | Psychometric Properties of the Chinese Version of Penn State [Electronic] Cigarette Dependence Index E-Cig Use | — | 2022-05-27 |